Hospital of Qingdao University, Qingdao, China.
Hospital of Qingdao University, Qingdao, China.
Biomed Pharmacother. 2020 Dec;132:110797. doi: 10.1016/j.biopha.2020.110797. Epub 2020 Oct 14.
China has one of the highest incidence rates of hepatocellular carcinoma (HCC) in the world. As most patients are diagnosed with advanced or unretractable HCC, systematic therapy is still the main treatment method for HCC. Currently, tyrosine kinase inhibitors (TKIs) and Immune checkpoint inhibitors (ICIs) are both the chief systematic therapy. And some studies have shown that the combination of TKIs and ICIs is more effective than monotherapy. The purpose of this review is to outline the rationale for the combination between lenvatinib and anti-PD-1(programmed cell death 1) and clinical trials to support this "golden combination". We also discuss the commonly treatment-emergent adverse events (AEs) and solutions for the patients with HCC who received the combination between lenvatinib and anti-PD-1 antibodies. Finally, we focus on the novel approaches, future perspectives and potential challenges about the combination of TKIs and ICIs.
中国是世界上肝细胞癌 (HCC) 发病率最高的国家之一。由于大多数患者被诊断为晚期或不可切除的 HCC，系统治疗仍然是 HCC 的主要治疗方法。目前，酪氨酸激酶抑制剂 (TKI) 和免疫检查点抑制剂 (ICI) 都是主要的系统治疗方法。一些研究表明，TKI 和 ICI 的联合治疗比单药治疗更有效。本综述的目的是概述仑伐替尼联合抗 PD-1（程序性细胞死亡 1）的理论基础，并提供支持这种“黄金组合”的临床试验。我们还讨论了接受仑伐替尼联合抗 PD-1 抗体治疗的 HCC 患者常见的治疗相关不良事件 (AE) 及其解决方案。最后，我们关注 TKI 和 ICI 联合治疗的新方法、未来前景和潜在挑战。
